PCN139 BUDGET IMPACT ANALYSIS OF NILOTINIB AS FIRST LINE TREATMENT OF NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) WITH HIGH RISK SOKAL SCORE IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.335
https://www.valueinhealthjournal.com/article/S1098-3015(19)32713-5/fulltext
Title : PCN139 BUDGET IMPACT ANALYSIS OF NILOTINIB AS FIRST LINE TREATMENT OF NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) WITH HIGH RISK SOKAL SCORE IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32713-5&doi=10.1016/j.jval.2019.09.335
First page :
Section Title :
Open access? : No
Section Order : 10273
Categories :
Tags :
Regions :
ViH Article Tags :